Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Malaysian Health Technology Assessment (MaHTAS)	First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022	WorkSafeBC	Lose-dose naltrexone as treatment for post-COVID conditions
2022	National Institute for Health and Care Excellence (NICE)	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022	Scottish Health Technologies Group (SHTG)	vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cerliponase Alfa - reassessment after the deadline (type 2 neuronal ceroid lipofuscinosis)]
2022	National Institute for Health and Care Excellence (NICE)	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2022	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 815
2022	NIHR Health Technology Assessment programme	Enhancing social-emotional health and wellbeing in the early years: a community-based randomised controlled trial (and economic) evaluation of the Incredible Years Infant and Toddler (0-2) Parenting Programmes
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022	National Institute for Health and Care Excellence (NICE)	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. NICE technology appraisal guidance 816
2022	NIHR Health Technology Assessment programme	Development and evaluation of machine learning methods in whole body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer (MAchine Learning In whole Body Oncology, MALIBO)
2022	NIHR Health Technology Assessment programme	Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence. NICE technology appraisal guidance 817
2022	NIHR Health Technology Assessment programme	FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the Effect on quality of life
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022	Agency for Care Effectiveness (ACE)	Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. NICE technology appraisal guidance 818
2022	Agency for Care Effectiveness (ACE)	Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022	National Institute for Health and Care Excellence (NICE)	Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. NICE technology appraisal guidance 819
2022	NIHR Health Technology Assessment programme	A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
2022	Agency for Care Effectiveness (ACE)	The PrecivityAD test for the prognosis of Alzheimer's disease
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022	National Institute for Health and Care Excellence (NICE)	Brolucizumab for treating diabetic macular oedema. NICE technology appraisal guidance 820
2022	National Institute for Health and Care Excellence (NICE)	KardiaMobile for detecting atrial fibrillation. NICE medical technologies guidance 64
2022	NIHR Health Technology Assessment programme	Fast-Forward: a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in women with early breast cancer
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022	Agency for Care Effectiveness (ACE)	Artificial intelligence and its clinical applications
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022	National Institute for Health and Care Excellence (NICE)	Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2022	Agency for Care Effectiveness (ACE)	3D printing and its clinical applications
2022	National Institute for Health and Care Excellence (NICE)	Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal). NICE technology appraisal guidance 822
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022	Agency for Care Effectiveness (ACE)	Overview of clinical applications of telemedicine
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2022	National Institute for Health and Care Excellence (NICE)	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 823
2022	National Institute for Health and Care Excellence (NICE)	Memokath 051 Ureter stent for ureteric obstruction. NICE medical technologies guidance 75
2022	Agency for Care Effectiveness (ACE)	Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2022	National Institute for Health and Care Excellence (NICE)	Dexamethasone intravitreal implant for treating diabetic macular oedema. NICE technology appraisal guidance 824
2022	National Institute for Health and Care Excellence (NICE)	Optilume for treating recurrent bulbar urethral strictures. NICE medical technologies guidance 73
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2022	Agency for Healthcare Research and Quality (AHRQ)	Diagnostic errors in the emergency department: a systematic review
2022	National Institute for Health and Care Excellence (NICE)	Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. NICE technology appraisal guidance 825
2022	National Institute for Health and Care Excellence (NICE)	GreenLight XPS for treating benign prostatic hyperplasia. NICE medical technologies guidance 74
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: amyotrophic lateral sclerosis with or without frontotemporal dementia NGS panel]
2022	Scottish Health Technologies Group (SHTG)	The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022	Center for Drug Evaluation (CDE)	Patient involvement in the health technology assessment process in Taiwan
2022	National Institute for Health and Care Excellence (NICE)	Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2022	National Institute for Health and Care Excellence (NICE)	Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer. NICE medical technologies guidance 72
2022	NIHR Health Technology Assessment programme	Gastric Bypass, adjustable gastric Banding or Sleeve gastrectomy surgery to treat severe and complex obesity: a multi-centre randomised controlled trial (The By-Band-Sleeve Study)
2022	NIHR Health Technology Assessment programme	POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes
2022	Agency for Care Effectiveness (ACE)	Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec (reassessment after the deadline: inherited retinal dystrophy)]
2022	Scottish Health Technologies Group (SHTG)	A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation
2022	National Institute for Health and Care Excellence (NICE)	Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy. NICE technology appraisal guidance 827
2022	NIHR Health Technology Assessment programme	The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2022	National Institute for Health and Care Excellence (NICE)	Ozanimod for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 828
2022	National Institute for Health and Care Excellence (NICE)	Faecal microbiota transplant for recurrent Clostridioides difficile infection. NICE medical technologies guidance 71
2022	NIHR Health Technology Assessment programme	E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022	Agency for Care Effectiveness (ACE)	Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 829
2022	Haute Autorite de sante (HAS)	[Transcranial magnetic stimulation (rTMS) in the treatment of adult treatment-resistant depression]
2022	NIHR Health Technology Assessment programme	Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2022	NIHR Health Technology Assessment programme	RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2022	National Institute for Health and Care Excellence (NICE)	Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 832
2022	NIHR Health Technology Assessment programme	Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodules
2022	Agency for Healthcare Research and Quality (AHRQ)	Evaluation of mental health mobile applications
2022	National Institute for Health and Care Excellence (NICE)	Zanubrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 833
2022	National Institute for Health and Care Excellence (NICE)	SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal). NICE technology appraisal guidance 834
2022	Malaysian Health Technology Assessment (MaHTAS)	Transcutaneous oxygen pressure monitoring (TcPO2)
2022	Agency for Healthcare Research and Quality (AHRQ)	Improving rural health through telehealth-guided provider-to-provider communication
2022	National Institute for Health and Care Excellence (NICE)	Fostamatinib for treating refractory chronic immune thrombocytopenia. NICE technology appraisal guidance 835
2022	Penn Medicine Center for Evidence-based Practice (CEP)	VTE chemoprophylaxis for patients undergoing elective spinal surgery
2022	Malaysian Health Technology Assessment (MaHTAS)	Sublingual immunotherapy (SLIT) for atopy (allergic rhinitis, eczema and asthma)
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Calcifediol (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2022	Agency for Healthcare Research and Quality (AHRQ)	Infection prevention and control for the emergency medical services and 911 workforce
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Patients with hip fracture from low-impact trauma: clinical management of anti-osteoporotic pharmacological treatment to prevent new fractures]
2022	National Institute for Health and Care Excellence (NICE)	Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 836
2022	National Institute for Health and Care Excellence (NICE)	Sleepio to treat insomnia and insomnia symptoms. NICE medical technologies guidance 70
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Video camera-assisted or electromagnetic placement of enteral feeding tubes
2022	Malaysian Health Technology Assessment (MaHTAS)	Mesenchymal stem cells for retinitis pigmentosa and other degenerative retina disease
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Isoflurane (sedation of mechanically ventilated patients) - Benefit assessment according to §35a Social Code Book V]
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Efficacy and safety of the pilates method in selected clinical conditions]
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. NICE technology appraisal guidance 837
2022	National Institute for Health and Care Excellence (NICE)	myCOPD for managing chronic obstructive pulmonary disease. NICE medical technologies guidance 68
2022	NIHR Health Technology Assessment programme	Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial (HEAT)
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Pneumocystis jirovecii pneumonia (PJP) prophylaxis
2022	Health Technology Wales (HTW)	Left atrial appendage occlusion in patients with atrial fibrillation
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V]
2022	National Institute for Health and Care Excellence (NICE)	Slow-release potassium bicarbonate-potassium citrate for treating distal renal tubular acidosis (terminated appraisal). NICE technology appraisal guidance 838